• Tue. Oct 17th, 2023

Maine Man Pleads Guilty in Trafficking

Avatar photo

ByDavid Brown

Aug 30, 2023
Maine Man Pleads Guilty in Trafficking
David Brown

Addressing his participation in a fentanyl trafficking network spanning northern New England, Douglas Morris, 33, of Bangor, Maine, filed a guilty plea in federal court in Boston. He is accused of conspiring to make available fentanyl and the fentanyl analog p-Fluorofentanyl. Judge Indira Talwani of the U.S. District Court heard the plea; the defendant will be sentenced on November 14, 2023. A grand jury of the United States convicted Morris in March 2022 along with five other individuals.

Maine Man Guilty in Fentanyl Trafficking: Hotel Parking Lot Busts

p-Fluorofentanyl was reportedly given to co-defendant Ivan Rodriguez Osorio by Morris in the parking lot of an Amesbury hotel in June 2021 with the intention of distributing it throughout Maine, according to court records. The drugs were then taken by law enforcement after Morris’ car was halted. Morris reportedly purchased nearly two kilos of fentanyl from Rodriguez Osorio in the same hotel parking lot in July 2021. Once more, state law enforcement stepped in and seized the narcotics.

Morris enters the case as the third defendant to enter a guilty plea. For this offense, a required minimum term of 10 years to life in prison, at least five years of supervised release, and a fine up to $10 million are the only available punishments.

A multi-agency task team composed of representatives from the federal, state, and local law enforcement agencies, known as the OCDETF team, carried out the operation. The main goal of OCDETF is to locate, destroy, and disrupt significant groups engaged in the illegal trade of drugs, weapons, and money. These organizations are mostly to blame for the country’s supply of illegal drugs. Until they are proven guilty beyond a reasonable doubt, the accused are deemed innocent.

 
Avatar photo

David Brown

With years of expertise in the field, i am bring a wealth of knowledge and insights to our platform. Our editor’s extensive research and understanding of the drug landscape ensure that their content is accurate, informative, and engaging.